Navigation Links
Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results

CAMBRIDGE, Mass., March 6 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the fourth quarter and year ended December 31, 2007. At December 31, 2007, Idenix's cash, cash equivalents and marketable securities totaled $112.0 million.
Significant company events for 2007 included:

-- The approval and launch of Sebivo(R) in major markets on a worldwide

basis, including China and the European Union. By year-end 2007,

Tyzeka(R)/Sebivo(R) (telbivudine) was approved in more than 50


-- The discontinuation of development of valopicitabine, or NM283, which

had been Idenix's lead drug candidate for the treatment of hepatitis C.

-- A strategic restructuring whereby Novartis Pharma AG assumed full

responsibility for the development, manufacturing and commercialization

activities relating to Tyzeka/Sebivo effective October 1, 2007 in

exchange for a royalty on worldwide product sales. As a result of these

changes, Idenix reduced its workforce by approximately 100 positions,

the majority of which supported the development and commercialization

of Tyzeka/Sebivo in the United States and Europe.

-- The expansion of Idenix's pipeline to include a novel non-nucleoside

reverse transcriptase inhibitor for the treatment of HIV-1 that is

currently in clinical development, and several novel direct-acting HCV

product candidates, including next-generation nucleoside/nucleotide

polymerase inhibitors and protease inhibitors that are in late-stage

preclinical testing.

"In 2007, Idenix experienced a great deal of change, which enabled us to reassess the strategic direction of our company and reevaluate our focus," said Jean-Pierre Sommadossi, Ph.D., chairman and chief executive officer of Idenix. "I am very pleased to report that the company continues to be grounded by a strong scientific foundation that enables us to rapidly discover novel antiviral drug candidates. As we begin 2008, we are a stronger, leaner organization that will devote all of our resources to the discovery and continued development of antiviral drugs for the treatment of HCV and HIV."

Financial Results

For the fourth quarter ended December 31, 2007, Idenix reported total revenues of $12.6 million, compared with total revenues of $15.3 million in the fourth quarter of 2006. Total revenues for the fourth quarter of 2007 consisted primarily of reimbursement by Novartis of expenses incurred by Idenix in connection with the development of Tyzeka(R)/Sebivo(R), the amortization of up front fees associated with development programs licensed by Novartis, and royalties associated with worldwide sales of Tyzeka/Sebivo. The $2.7 million reduction in total revenues for the fourth quarter of 2007 as compared to the fourth quarter of 2006 is due primarily to lower development expenses associated with licensed programs and subsequent reimbursement of such expenses by Novartis.

Idenix reported a net loss of $17.5 million, or a loss of $0.31 per basic and diluted share for the fourth quarter ended December 31, 2007, compared to a net loss of $23.6 million, or a loss of $0.42 per basic and diluted share for the fourth quarter ended December 31, 2006. The $6.1 million reduction in net loss for the fourth quarter of 2007 as compared to the fourth quarter of 2006 is due primarily to lower selling, general and administrative expenses incurred as a result of a restructuring that the company began implementing at the end of the third quarter of 2007. The net loss for the fourth quarter of 2007 included $2.3 million in restructuring charges primarily related to severance costs, $1.5 million associated with the amortization of a portion of a proposed non-binding settlement with the University of Alabama Birmingham Research Foundation and related entities regarding the ongoing telbivudine- related contractual dispute and litigation, and $1.8 million of expenses associated with an uncertain international tax position. If either the proposed settlement is not completed on terms favorable to Idenix and/or the view on the company's international tax position changes, such accruals may be adjusted in future periods.

For the year ended December 31, 2007, Idenix reported total revenues of $68.0 million, compared with total revenues of $67.4 million for the year ended December 31, 2006. The company reported a net loss of $82.5 million, or a loss of $1.47 per basic and diluted share for the year ended December 31, 2007, compared with $75.1 million, or a loss of $1.34 per basic and diluted share for the year ended December 31, 2006. The net loss reported for the year ended December 31, 2007 included $8.7 million in restructuring charges, which includes the impairment of certain assets equal to approximately $2.1 million.

2008 Financial Guidance

Idenix estimates that the restructuring implemented in the fourth quarter of 2007 will result in annual savings of $40 million to $45 million, including associated third party and marketing costs. Idenix anticipates ending 2008 with approximately $50 million of cash, cash equivalents and marketable securities, assuming no milestone payments, license fees, reimbursement for development programs, and no financing activities during 2008.

Conference Call and Webcast Information

Idenix will hold a conference call today at 4:30 p.m. ET. To access the call please dial 800-471-3635 U.S./Canada or 706-758-9475 International and enter passcode 33321401. To listen to a live webcast of the call, go to "Calendar of Events" in the Idenix Investor Center at Please log in approximately 10 minutes before the call to ensure a timely connection. A replay of the conference call and webcast will be available until March 20, 2008. To access the replay, please dial 800-642-1687 U.S./Canada or 706-645- 9291 International and enter the passcode 33321401.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus and HIV. For further information about Idenix, please refer to

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward- looking statements can be identified by the use of forward-looking terminology such as "expect," "may," "plans," "anticipates," "preliminary," "will," or similar expressions, or by express or implied statements with respect to the company's clinical development programs or commercialization activities in HIV or hepatitis C, or any potential pipeline candidates and expectations with respect to additional milestone payments, potential payments related to a settlement proposal, assessment of uncertain tax positions and cash balances at the end of 2008. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantees that historical sales of Tyzeka/Sebivo will in any way suggest future royalty payments or royalty rates owed to the company, or that the company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization. In particular, management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on its collaboration with Novartis Pharma AG; changes in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's annual report on Form 10-K for the year ended December 31, 2006 and the Quarterly Report on Form 10-Q for the quarter ended September 30, 2007, each as filed with the Securities and Exchange Commission (SEC) and other filings that the company makes with the SEC.

All forward-looking statements reflect the company's expectations only as of the date of this release and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. Idenix anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Idenix Pharmaceuticals' Contacts:

Media: Teri Dahlman (617) 995-9905

Investors: Amy Sullivan (617) 995-9838





Three Months Ended Years Ended

December 31, December 31,

2007 2006 2007 2006


Collaboration revenue -

related party $12,573 $14,826 $64,751 $66,724

Product sales -- 424 3,187 424

Government research grants 29 58 90 229

Total revenues 12,602 15,308 68,028 67,377

Operating expenses (1):

Cost of sales 1,487 62 2,001 62

Research and development 20,294 23,067 85,839 96,080

Selling, general and

administrative 9,278 18,227 63,348 56,954

Restructuring and impairment

charges 2,305 -- 8,744 --

Total operating expenses 33,364 41,356 159,932 153,096

Loss from operations (20,762) (26,048) (91,904) (85,719)

Investment and other income, net 4,389 2,270 9,887 9,487

Loss before income taxes (16,373) (23,778) (82,017) (76,232)

Income tax benefit (expense) (1,122) 197 (498) 1,145

Net loss $(17,495) $(23,581) $(82,515) $(75,087)

Basic and diluted net loss

per share: ($0.31) ($0.42) ($1.47) ($1.34)

Shares used in calculation of basic

and diluted net loss per share: 56,189 56,078 56,169 56,005

(1) Stock-based compensation

expenses included in operating

expenses amounted to approximately:

Research and development $560 $646 $3,005 $2,892

Selling, general and administrative 899 1,218 4,758 5,745

Restructuring and impairment charges -- -- 968 --





December 31, December 31,

2007 2006


Cash and cash equivalents $48,260 $55,892

Marketable securities 39,862 71,251

Receivables from related party 11,196 12,035

Other current assets 4,401 8,427

Total current assets 103,719 147,605

Intangible assets, net 13,548 --

Property and equipment, net 15,461 17,448

Marketable securities, non-current 23,882 59,208

Other assets 3,930 4,204

Total assets $160,540 $228,465


Accounts payable and accrued expenses $21,809 $23,429

Deferred revenue, related party 8,372 13,490

Other current liabilities 553 527

Total current liabilities 30,734 37,446

Long-term obligations 19,107 8,523

Deferred revenue, related party, net of

current portion 41,861 40,471

Total liabilities 91,702 86,440

Stockholders' equity 68,838 142,025

Total liabilities and stockholders' equity $160,540 $228,465

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
2. Idenix Pharmaceuticals to Present at the JP Morgan 26th Annual Healthcare Conference
3. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Notice of Bradmer Pharmaceuticals Conference Call
6. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
7. ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter 2007 Financial Results
8. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
9. Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and Chairman
10. MAP Pharmaceuticals Reports 2007 Fourth Quarter and Year End Financial Results
11. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
Post Your Comments:
(Date:10/13/2017)... ... ... While it’s often important to take certain medications during the night, finding them ... a solution. , She developed a prototype for MOTION LIGHT-UP PILL BOX to provide ... need to turn on a light when taking medication during the night, allowing the ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... certification process to promote standards of excellence for the field of eating disorders, ... March 22 – 25, 2018 in Orlando, Florida at the Omni Resort at ...
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton ... staged a mock evacuation of the facility as part of a disaster drill on ... Echo Hose EMS and Shelton City Emergency Manager, as well as the Connecticut ...
(Date:10/13/2017)... BASKING RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... second annual Holly Day Market. Featuring a collection of specialty vendors and unique items ... myriad of personalized and quality-focused health and wellness services offered by the VNA. ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
(Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... ...
Breaking Medicine Technology: